Actively supporting McKinsey and AD Little with guidance on pharmaceutical portfolio management for value. Whether it’s operating model development, brand strategy and/or lifecycle management, Jill Jobbins Advisory can support you in your quest to maximize portfolio value bringing positive outcomes to your bottom line.
News
Jill Jobbins Advisory supports Insmed Expansion in Asia
Insmed has engaged DKSH Korea Ltd. to provide services to support an expanded access program on a named patient basis in South Korea.
CICERO GROUP WELCOMES JILL JOBBINS TO SENIOR ADVISORS
September, 2019 (SALT LAKE CITY) – Cicero Group, a premier management consulting firm focused on implementing data-driven strategies, has named Jill Jobbins, Principal at Jill Jobbins Advisory, to its council of senior advisors. Jill leverages over 15 years of experience in managing global pharmaceutical product portfolios for value. Jill is a pace setter in business management focused on creating strategy and unique operating models that deliver maximum financial outcomes for global assets.
“Jill has decades of experience helping to boost pharmaceutical and health care product growth across the industry,” said Dr. Trent Kaufman, CEO of Cicero Group. “She is an incredible asset to have on our council of senior advisors and we look forward to accelerating our health care expertise.”
Cicero Group is a premier management consulting firm focused on implementing data-driven strategies for a broad mix of private, public, and social sector organizations across the globe. Cicero Group is headquartered in Salt Lake City, Utah, with additional offices in Dallas, Texas, and Washington D.C. Cicero Group uses data and experience to generate insights, create actionable strategies, and drive transformation with an overarching purpose of helping people create and continuously deliver extraordinary results.
Expanding Commercial Reach
An aspect of lifecycle management is to expand the geographic commercial reach of the drug by considering effective approaches to ensure patient access. For example, Early Access Programs can be immensely useful in early market penetration leading to increased acceptance by physicians and patients after the commercial launch of the product. If you require critical thinking on the development of operating models that allow expanded commercial reach at various lifecycle stages, I look forward to hearing from you!
Networking at HBA WOTY Event on May 3rd
The HBA – WOTY event is an interactive luncheon program that attracts nearly 2,500 top healthcare and life science industry leaders and is now sold-out! Let’s connect there!
Jill Jobbins Advisory 